TY - JOUR T1 - COVID-19 Implications of the Physical Interaction of Artificial Fog on Respiratory Aerosols JF - medRxiv DO - 10.1101/2021.03.18.21253891 SP - 2021.03.18.21253891 AU - Matthew Loss AU - Mark Katchen AU - Ilan Arvelo AU - Phil Arnold AU - Mona Shum Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/20/2021.03.18.21253891.abstract N2 - Introduction Artificial fog is used in the film, television, and live entertainment industries to enhance lighting, as a visual effect, and to create a specific sense of mood or atmosphere. This study investigated whether the suspension time of respiratory aerosols spiked with tagged DNA tracers would change in the presence of glycerin- or glycol-containing artificial fogs.Methods & Materials Respiratory aerosols with tagged DNA tracers were sprayed into a closed environment without and with glycerin- or glycol-containing artificial fog, with air samples taken at regular intervals to determine the decay of tagged DNA tracer over time. The study treatments included Control (no fog), Glycerin Low (3 mg/m3), Glycerin High (∼15 mg/m3), Glycol Low (∼5 mg/m3), and Glycol High (∼40 mg/m3).Results All artificial fog treatments had lower mean log reduction curves compared to the Control treatment. Compared to the Control and Glycerin Low treatments, the differences in mean log reduction for nearly all other artificial fog treatments were statistically significant (p<0.001); the difference between Control and Glycerin Low treatments was not statistically significant (p=0.087). The differences in mean log reduction between treatments using the same artificial fog type were not statistically significant.Conclusion Artificial fog use does not increase suspension time of respiratory aerosols, and therefore does not appear to increase the risk of airborne transmission of diseases from respiratory aerosols, such as COVID-19. Of the two types of artificial fogs investigated, that containing glycol decreased suspension time more than that containing glycerin. In practice, the additional reduction in suspension time provided by the physical interaction of respiratory aerosols with artificial fog does not suggest any practical benefit for using artificial fog as a control measure.Competing Interest StatementAuthors ML, IA, PA, and MS had financial support from IATSE Local 891, DGC-BC, and UBCP/ACTRA for the submitted work; non-financial support from CITC & Omnitec Design was provided during the conduct of the study; outside the submitted work, ML, MK, and MS have performed consultancy services for Apple, Amazon Inc., IATSE Local 891, NBCUniversal, Netflix, Paramount Pictures, Sony Pictures, The Walt Disney Company, and Warner Bros Entertainment Inc. in the past three years; no other relationships or activities that could appear to have influenced the submitted work.Funding StatementThis work was partially financially supported by the International Alliance for Theatrical Stage Employees (IATSE), Local 891, Directors Guild of Canada - BC (DGC-BC), and the Alliance of Canadian Cinema, Television and Radio Artists Union of British Columbia Performs (UBCP/ACTRA). The tagged DNA tracers, sampling equipment, and laboratory analysis was provided by SafeTraces Inc. The artificial fog fluids, fog machines, and portable air cleaner were provided by CITC and Omnitec Design.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not Applicable - no IRB/oversight body required for the study given study design and scope.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData may be available upon request, and is provided on a case by cases basis. ER -